NCT06290388View on ClinicalTrials.gov

Study of 23ME-01473 in Patients With Advanced Solid Malignancies

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

November 10, 2024

Study Completion Date

November 10, 2024

Conditions
Solid Tumor
Interventions
DRUG

23ME-01473

23Me-01473 given by intravenous infusion

Trial Locations (3)

49546

START Midwest, Grand Rapids

78229

START Center for Cancer Care, San Antonio

97239

Oregon Health & Science University, Portland

Sponsors

Lead Sponsor

23andMe, Inc.
All Listed Sponsors
lead

23andMe, Inc.

INDUSTRY